[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356658-105":59,"doc-detail-356658-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","suppression-of-ltbp1-enhances-the-sensitivity-of-bladder-cancer-to-cisplatin","Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin","","Cisplatin-based chemotherapy is a key treatment for advanced bladder cancer, yet many patients fail due to chemoresistance. Proteomics analysis of cisplatin-naïve and resistant clinical bladder cancer tissues, together with integrated GEO and TCGA datasets, identified LTBP1 as a candidate chemoresistance-associated gene. LTBP1 expression correlates with clinical stage and survival. LTBP1 knockdown suppresses malignant behaviors and chemoresistance via TGF-β-mediated EMT. In vivo tumor and lung metastasis models show that combining LTBP1 inhibition with cisplatin markedly restricts tumor growth and metastasis.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/suppression-of-ltbp1-enhances-the-sensitivity-of-bladder-cancer-to-cisplatin/356658/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/suppression-of-ltbp1-enhances-the-sensitivity-of-bladder-cancer-to-cisplatin/356658.png","ImageObject",300,407,{"name":92,"@type":93},"Taylor Morgan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why study LTBP1 in bladder cancer chemoresistance?","Question",{"text":112,"@type":113},"Cisplatin-based chemotherapy often fails because chemoresistance develops. The study aimed to identify drivers and counterstrategies to improve patient prognosis, and found LTBP1 linked to chemoresistance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was LTBP1 identified as a chemoresistance-associated gene?",{"text":117,"@type":113},"Proteomics analysis compared cisplatin-naïve and resistant bladder cancer tissues, and the GEO and TCGA datasets were integrated to reveal LTBP1 as a potential associated gene.",{"name":119,"@type":110,"acceptedAnswer":120},"What effect does LTBP1 knockdown have on bladder cancer cells and therapy response?",{"text":121,"@type":113},"LTBP1 knockdown inhibited proliferation, migration, invasion, and chemoresistance in bladder cancer cells, acting through TGF-β-mediated epithelial-mesenchymal transition (EMT).",{"name":123,"@type":110,"acceptedAnswer":124},"What did the animal models show when LTBP1 inhibition was combined with cisplatin?",{"text":125,"@type":113},"Subcutaneous tumor and lung metastasis mouse models demonstrated that LTBP1 inhibition combined with cisplatin significantly reduced tumor growth and metastasis.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},356658,1790921096,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099523885336,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSuppression of LTBP1 enhances the sensitivity of bladder cancer tocisplatin  \nZongyang Li1,6, YongboYu2,6, Fang Liu3, Yushu Wu4, Yunjiang Zang2, Yanhong Ding5􀀍 & Zhilei Zhang2􀀍  \nCisplatin-based chemotherapy is the primary treatment for advanced bladder cancer; however, numerous patients experience treatment failure because of chemoresistance. Therefore, it is crucial to identify drivers of chemoresistance and determine strategies to counteract them to improve prognosis in bladder cancer patients. This study performed proteomics analysis of clinical samples of cisplatinnaïve and resistant bladder cancer tissues. Furthermore, the GEO and TCGA datasets were integrated, which revealed latent transforming growth factor β binding protein 1 (LTBP1) as a potential gene associated with chemoresistance in bladder cancer. LTBP1 expression was correlated with clinical stage and patient survival. LTBP1 knockdown in bladder cancer cells inhibited proliferation, migration, invasion, and chemoresistance viaTGF-β-mediated epithelial-mesenchymal transition. Subcutaneous tumor and lung metastasis mouse models revealed that LTBP1 inhibition combined with cisplatin treatment significantly inhibited tumor growth and metastasis. Higher LTBP1 expression is associated with a worse prognosis and advanced stage in bladder cancer patients. In conclusion, this study revealed that LTBP1 may be a potential target for alleviating chemoresistance in bladder cancer.  \nKeywords LTBP1, Chemotherapy resistance, Bladder cancer, EMT  \nBladder cancer is one of the most common and deadly urologic cancers, posing significant problems for prevention and treatment1. The literature has indicated that about 75% of bladder cancer cases are first identified as non-muscle-invasive bladder cancer (NMIBC)2. Patients with NMIBC are susceptible to tumor recurrence post-treatment and may advance to muscle-invasive bladder cancer (MIBC)3,4. Currently, the standard treatment for MIBC is neoadjuvant chemotherapy followed by radical cystectomy, which mainly comprises platinum-based regimens, such as gemcitabine plus cisplatin (GC). Neoadjuvant chemotherapy with the GC regimen can reduce tumor size and enhance long-term survival in MIBC patients5. Furthermore, aside from enfortumab vedotin plus pembrolizumab, GC remains the recommended treatment strategy for metastatic urothelial carcinoma of the bladder in patients who can tolerate cisplatin6–8. However, irrespective of the chemotherapy regimen, drug resistance inevitably develops over time, a major challenge in cancer treatment that can result in therapeutic failure. Despite comprehensive interventions, the 5-year survival rate for MIBC patients remains unsatisfactory at approximately 50%9, which is closely related to chemoresistance in tumors. Therefore, it is crucial to identify mechanisms of chemoresistance to provide novel theoretical evidence for bladder cancer drug therapy and personalized chemotherapy regimens.  \nLatent transforming growth factor β binding protein 1 (LTBP1) is a large multidomain protein that belongs to the family of latent TGF-β binding proteins (LTBPs) . It is the primary component of the extracellular matrix (ECM)10. LTBP1 modulates TGF-β activity indirectly by interacting with the ECM, hence affecting TGF-β’s secretion, activation, and functional expression11, 12. The literature has reported that LTBP1 is significantly related to tumor occurrence, development, and drug resistance via various mechanisms (such as TGF-β signaling regulation), as well as epithelial-mesenchymal transition (EMT) processes and tumor microenvironment (TME) modulation13–15. However, the role of LTBP1 in bladder cancer remains elusive.  \n1Department of Urology, West Coast Second Hospital of Qingdao University Medical Group, Qingdao 266499, China. 2Department of Urology, The First Affiliated Hospital of Shandong Second Medical University, Weifang 261041","cbCaipZSbKeuso15","https://ap.wps.com/l/cbCaipZSbKeuso15","pdf",4448029,13,"English","# Materials and methods\n## Tissue samples and cell culture","[{\"question\":\"Why study LTBP1 in bladder cancer chemoresistance?\",\"answer\":\"Cisplatin-based chemotherapy often fails because chemoresistance develops. The study aimed to identify drivers and counterstrategies to improve patient prognosis, and found LTBP1 linked to chemoresistance.\"},{\"question\":\"How was LTBP1 identified as a chemoresistance-associated gene?\",\"answer\":\"Proteomics analysis compared cisplatin-naïve and resistant bladder cancer tissues, and the GEO and TCGA datasets were integrated to reveal LTBP1 as a potential associated gene.\"},{\"question\":\"What effect does LTBP1 knockdown have on bladder cancer cells and therapy response?\",\"answer\":\"LTBP1 knockdown inhibited proliferation, migration, invasion, and chemoresistance in bladder cancer cells, acting through TGF-β-mediated epithelial-mesenchymal transition (EMT).\"},{\"question\":\"What did the animal models show when LTBP1 inhibition was combined with cisplatin?\",\"answer\":\"Subcutaneous tumor and lung metastasis mouse models demonstrated that LTBP1 inhibition combined with cisplatin significantly reduced tumor growth and metastasis.\"}]","Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin | PDF",1790126662,33,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/604d4a877496c90c475db8a5cbfa6637.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53e10b06dd5b7153eed806508eb4b699.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f1115ab1b20816b738aafb08a428249.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97c74bb4ac4f81e240ef2e821c86340a.webp",980,1287]